Keywords: Hikma, Baxter Healthcare, USA, Antitrust, M&A, Phenytoin, Promethazine

Hikma must sell two drugs as condition of Baxter Healthcare acquisition, says US antitrust body

Article | 29 April 2011

Print This

The USA’s Federal Trade Commission will require Jordan-based drugmaker Hikma Pharmaceuticals (LSE: HIK; Dubai: HIK) to divest two ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in